创新驱动未来 Innovation Drives Future

佰睿壹生物 Bio-reinnovation

用技术创新构建ADC的未来 Building the Future of ADC with Innovation

佰睿壹生物专注于抗体偶联药(ADC)的底层技术创新和下一代ADC药物的研发，致力于为全球患者带来突破性的治疗方案。 Bio-reinnovation focuses on fundamental technological innovation in Antibody-Drug Conjugates (ADC) and the development of next-generation ADC therapeutics, committed to bringing breakthrough treatments to patients worldwide.

Empowering the Future of
ADC Innovation 用技术创新构建
ADC的未来

佰睿壹生物专注于抗体偶联药(ADC)的底层技术创新和双载荷ADC药物开发。作为抗体链间二硫键选择性还原技术的开拓者，我们开发了系统性化学定点偶联技术平台 MCLICK，该平台能够实现非常多样的ADC DAR值和双载荷ADC的比例，支持单载荷AXC和双载荷ADC的精细化设计。同时，抗体链间二硫键选择性还原/偶联的技术路径具有卓越的兼容性、广泛的适用性和明确且非常友好的CMC成本优势，是赋能First-in-Class和Best-in-Class ADC差异化创新的强大工具。 Bio-reinnovation focuses on fundamental technological innovation in Antibody-Drug Conjugates (ADC) and the development of dual-payload ADC drugs. As a pioneer of interchain disulfide bond selective reduction technology, we have developed the systematic site-specific chemical conjugation platform MCLICK, which enables highly diverse ADC DAR values and dual-payload ADC ratios, supporting the precise design of both single-payload AXC and dual-payload ADCs. Meanwhile, the interchain disulfide bond selective reduction/conjugation approach offers excellent compatibility, broad applicability, and clear, highly favorable CMC cost advantages, making it a powerful tool to empower First-in-Class and Best-in-Class ADC differentiated innovation.

系统性化学定点偶联平台 Systematic Site-specific Conjugation

ADC 创新技术平台 ADC Innovation Platforms

佰睿壹生物ADC创新技术平台包括化学定点偶联技术平台 MCLICK™、亲水性连接子-毒素技术平台 HILT、超低DAR值AXC技术平台 UDAC 和双载荷ADC技术平台 DPAC。其中MCLICK™由一揽子化学定点偶联技术组成，可以实现IgG1类单、双抗从1到8任意DAR值的AXC定点定量偶联。通过不同技术的组合，MCLICK™还能用于双载荷或者多载荷ADC的制备，可以实现两种或者三种不同作用机制药物分子的偶联和比例的灵活调节。 Bio-reinnovation's ADC innovation platforms include the chemical site-specific conjugation platform MCLICK™, the hydrophilic linker-toxin platform HILT, the ultra-low DAR AXC platform UDAC, and the dual-payload ADC platform DPAC. Among them, MCLICK™ consists of a suite of chemical site-specific conjugation technologies, enabling site-specific and quantitative conjugation of IgG1 monoclonal and bispecific antibodies with any DAR value from 1 to 8. By combining different technologies, MCLICK™ can also be used for the preparation of dual- or multi-payload ADCs, allowing flexible conjugation and ratio adjustment of two or three payloads with different mechanisms of action.

技术优势 Technical Advantages

ADC领域痛点 ADC Challenges

单载荷ADC耐药性问题 Resistance in Single-Payload ADCs
收率较低、酶催化偶联技术导致工艺成本较大 Low Yield and High Process Costs with Enzyme-Catalyzed Conjugation
双载荷ADC可选DAR值较为单一 Limited DAR Options in Dual-Payload ADCs
传统巯基偶联技术的不足 Limitations of Traditional Thiol Conjugation

佰睿壹优势 Our Advantages

双载荷ADC可解决耐药性问题 Dual-Payload ADCs Address Resistance
巯基化学定点偶联技术，大幅降低CMC成本 Site-Specific Thiol Conjugation Reduces CMC Costs
最丰富的的双载荷ADC可选DAR值比例 Most Diverse DAR Ratio Options for Dual-Payload ADCs

Systematic Site-Specific Platform 系统性化学定点偶联平台

MCLICK™

支持多种DAR值及双载荷ADC比例的灵活定制，满足最前沿的复杂药物设计需求。 Flexible customization of various DAR values and dual-payload ADC ratios to meet the most advanced complex drug design needs.

DAR 1

DAR 1 + DAR 1 DAR 1 + DAR 2 DAR 1 + DAR 4 DAR 1 + DAR 6

DAR 2

DAR 2 + DAR 1 DAR 2 + DAR 2 DAR 2 + DAR 4 DAR 2 + DAR 6

DAR 4

DAR 4 + DAR 1 DAR 4 + DAR 2 DAR 4 + DAR 4

DAR 6

DAR 6 + DAR 1 DAR 6 + DAR 2

基于链间二硫键高度选择性还原Highly selective interchain disulfide bond reduction

兼容所有巯基反应性LDCompatible with all thiol-reactive LDs

DAR值选择丰富，均一性高Rich DAR options and high homogeneity

双载荷ADC比例调节灵活性高Highly flexible dual-payload ADC ratio adjustment

适用多种IgG1工程化抗体骨架Applicable to various IgG1 engineered antibody scaffolds

工艺简洁稳健，成本友好Simple, robust process and cost-effective

技术对照矩阵 Technology Comparison Matrix

告别传统的妥协。佰睿壹生物 MCLICK™ 平台在所有关键维度上均展现出了压倒性的优势。 Say goodbye to traditional compromises. Bio-Reinno's MCLICK™ platform demonstrates overwhelming advantages across all key dimensions.

关键特性Key Feature	MCLICK™ 佰睿壹生物独家 Bio-Reinno Exclusive	传统巯基 (示例)Traditional Thiol	酶介导 (示例)Enzyme-mediated
DAR 灵活性 (单/双载荷)DAR Flexibility (Mono/Dual)	极高Excellent	受限Limited	中等Moderate
无酶工艺纯化Enzyme-free Process	支持Yes	支持Yes	不支持No
抗体兼容性Antibody Compatibility	完美兼容Excellent	良好Good	受限Limited
多载荷适用性Multi-payload Applicability	完美支持Yes	不支持No	受限Limited
CMC 成本效益与收率CMC Cost Efficiency & Yield	极高High	中等Moderate	较低Lower

产品管线 Product Pipeline

我们的双有效载荷ADC管线经过精心设计，通过创新的MOA组合，针对高发病率、异质性强、耐药性高的肿瘤，显著拓展适应症范围。通过克服TOP1耐药、优于单载荷ADC，并与免疫治疗协同，致力于解决未满足的医疗需求。 Our dual payload ADC pipeline leverages innovative MOA combinations to address tumors with high incidence, strong heterogeneity, and significant drug resistance, aiming to provide superior treatment options and address unmet medical needs.

更丰富的 MOARicher MOA

克服耐药性Overcome Resistance

克服肿瘤异质性Overcome Heterogeneity

增强 ICD 效应Enhance ICD

载荷作用机制 (Dual-Payload Synergy)Mechanism of Action (Dual-Payload Synergy)

TOP1i MTA

TOP1i DDRi

MTA MTA

MTA DDRi

ADC/MOAADC/MOA

研发阶段Discovery

先导优化Lead Opt.

临床前Preclinical

临床验证Clinical

适应症Indication

BP100101

TOP1i + MTA

GCCRCPAAD

BP100201

TOP1i + MTA

TNBCUCCC

BP100301

TOP1i + MTA

NSCLCmBCUCGCCRC

BP100401

TOP1i + MTA

TNBCOCNSCLC

BP100901

TOP1i + MTA

TNBCNSCLCUCOCCRC

创新驱动未来 Innovation Drives Future

佰睿壹生物 Bio-reinnovation

Empowering the Future of ADC Innovation 用技术创新构建 ADC的未来

ADC 创新技术平台 ADC Innovation Platforms

技术优势 Technical Advantages

ADC领域痛点 ADC Challenges

佰睿壹优势 Our Advantages

技术对照矩阵 Technology Comparison Matrix

产品管线 Product Pipeline

Empowering the Future of
ADC Innovation 用技术创新构建
ADC的未来